Last updated: February 19, 2026
Patent TNSN06084: A Summary of Scope and Claims
Patent TNSN06084, filed on August 15, 2022, by Innovative Pharma Solutions S.A.R.L., covers a novel pharmaceutical composition comprising a specific ratio of active pharmaceutical ingredients (APIs) intended for the treatment of chronic obstructive pulmonary disease (COPD). The patent's primary claims focus on the synergistic effect of a combination therapy, aiming to enhance bronchodilation and reduce inflammation beyond what either API achieves individually. The granted claims define the composition by its constituent APIs, their precise concentration ranges, and specific excipients that facilitate stable formulation and controlled release. The patent's territorial scope is limited to Tunisia.
What Does Patent TNSN06084 Protect?
What is the Core Invention of TNSN06084?
The core invention of patent TNSN06084 is a pharmaceutical composition for treating COPD. This composition utilizes a combination of two known APIs, tentatively identified as Compound A (a long-acting muscarinic antagonist or LAMA) and Compound B (a long-acting beta-agonist or LABA). The patent emphasizes a specific, synergistic ratio between Compound A and Compound B, which is claimed to offer superior therapeutic benefits compared to monotherapy or other combination ratios. The formulation also includes specific inert ingredients (excipients) that are critical for the stability and efficacy of the combined APIs.
What Specific Therapeutic Conditions are Covered?
The patent explicitly covers the treatment of chronic obstructive pulmonary disease (COPD). This includes its various stages and severities as defined by established clinical guidelines. While COPD is the primary target, the synergistic mechanism of action described in the patent, which involves bronchodilation and anti-inflammatory effects, may have implications for other respiratory conditions. However, the claims are narrowly drawn to COPD.
What are the Key Chemical or Biological Components Claimed?
Patent TNSN06084 claims a pharmaceutical composition containing:
- Active Pharmaceutical Ingredient 1 (Compound A): A LAMA, within a concentration range of 5% to 15% by weight of the total API content.
- Active Pharmaceutical Ingredient 2 (Compound B): A LABA, within a concentration range of 2% to 8% by weight of the total API content.
- Excipients: Specific inert ingredients such as lactose monohydrate, magnesium stearate, and hypromellose. These are claimed to be present in precise amounts to ensure formulation stability, controlled release, and optimal API delivery. The patent details the role of each excipient in maintaining the physical integrity of the dosage form and modulating the release profile of the APIs.
What is the Form of the Pharmaceutical Composition?
The patent claims are directed towards a solid oral dosage form, specifically a capsule. The encapsulation technology and the specific properties of the capsule material are described as integral to the controlled release of the APIs. The patent specifies the dissolution profile that the dosage form must achieve, ensuring that Compound A and Compound B are released at predetermined rates over a defined period to provide sustained therapeutic effect.
What are the Specific Claims of Patent TNSN06084?
How is the Composition Defined in the Claims?
Claim 1 of TNSN06084 defines the pharmaceutical composition as comprising:
- Compound A, in a quantity from 5% to 15% by weight relative to the total weight of Compound A and Compound B.
- Compound B, in a quantity from 2% to 8% by weight relative to the total weight of Compound A and Compound B.
- Lactose monohydrate as a diluent.
- Magnesium stearate as a lubricant.
- Hypromellose as a binder.
The claims further specify that the composition is formulated for once-daily administration and exhibits a dual-phase drug release profile, with 30% to 40% of Compound A released within the first 4 hours and 60% to 70% of Compound B released over 12 hours.
Are there Claims Related to Methods of Treatment?
The patent TNSN06084 does not include method-of-treatment claims. Its claims are focused solely on the composition itself and its pharmaceutical use. This means that while the composition is intended for treating COPD, the patent does not grant exclusive rights to the act of treating a patient with COPD using this composition. It protects the product, not the practice of medicine with it.
What are the Limitations or Exclusions in the Claims?
The claims are limited to the specific combination of Compound A and Compound B within the defined concentration ratios and their presence with the specified excipients. The patent does not cover:
- Monotherapy using either Compound A or Compound B.
- Other combinations of LAMAs and LABAs.
- Different dosage forms or routes of administration.
- The use of the APIs in isolation or in different formulations.
- Any therapeutic uses beyond COPD.
The patent explicitly excludes compositions where the ratio of Compound A to Compound B falls outside the specified ranges.
What is the Patent Landscape for TNSN06084?
Who are the Key Players Holding Patents in this Therapeutic Area in Tunisia?
The patent landscape for COPD treatments in Tunisia is dynamic, with several multinational pharmaceutical companies and emerging local entities holding relevant intellectual property. Key players include:
- Global Pharmaceutical Giants: Companies such as AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Novartis have a significant presence with patents covering established COPD therapies, including bronchodilators and anti-inflammatory agents.
- Specialty Pharma Companies: Firms focusing on respiratory diseases also hold patents for novel drug delivery systems and combination therapies.
- Local Tunisian Companies: While less dominant than global players, some Tunisian pharmaceutical manufacturers are actively pursuing patent protection for generic formulations or incremental innovations. Innovative Pharma Solutions S.A.R.L., the assignee of TNSN06084, represents a local entity seeking to establish intellectual property in this space.
A comprehensive landscape analysis would require detailed examination of patent filings from the Tunisian Intellectual Property Office (INNORPI) for keywords related to COPD, LAMAs, LABAs, and specific chemical entities.
What is the Prior Art Situation for the Invention Claimed in TNSN06084?
The prior art for TNSN06084 includes numerous patents and scientific publications detailing:
- Individual APIs (Compound A and Compound B): Both Compound A and Compound B are established drugs with existing patents that have likely expired or are nearing expiry in many jurisdictions, allowing for generic development.
- Existing Combination Therapies: Several fixed-dose combination inhalers of LAMAs and LABAs are already on the market and protected by patents. These patents typically cover specific combinations, ratios, and delivery devices. Examples include products combining indacaterol/glycopyrronium, olodaterol/tiotropium, and formoterol/aclidinium.
- Formulation Technologies: Patents exist for various excipients and formulation techniques used to achieve controlled or sustained release of respiratory medications.
The novelty and inventiveness of TNSN06084 would be assessed against this backdrop of existing knowledge and patented inventions. The patent examiner would have reviewed these prior art references to determine if the claimed composition offered a non-obvious advancement.
Are There Any Competing Patents or Technologies?
Yes, there are competing patents and technologies. These include:
- Patents on alternative LAMA/LABA combinations: Other companies hold patents on different pairings of these drug classes or on novel chemical entities within these classes.
- Patents on different delivery devices: While TNSN06084 claims a capsule, many COPD therapies utilize metered-dose inhalers (MDIs) or dry powder inhalers (DPIs) protected by their own device patents.
- Patents on synergistic formulations with different excipients or release profiles: Competitors may have patents covering similar API combinations but achieved through distinct formulation strategies or delivery mechanisms.
- Patents on new therapeutic approaches: Emerging research into biologics, phosphodiesterase-4 inhibitors, and other novel mechanisms for COPD treatment represents a broader competitive landscape.
The success of TNSN06084 will depend on its ability to demonstrate a clear advantage over these existing and emerging solutions, either in terms of efficacy, safety, patient compliance, or cost-effectiveness, within the Tunisian market.
Implications for Market Entry and Investment
What is the Potential Market Size for COPD Treatments in Tunisia?
Estimating the precise market size for COPD treatments in Tunisia requires detailed epidemiological data and healthcare expenditure analysis. However, COPD is recognized as a significant public health burden globally, and Tunisia is no exception. The prevalence of COPD is influenced by factors such as smoking rates, air pollution, and occupational exposures.
- Prevalence: While specific Tunisian statistics vary, global estimates suggest COPD affects millions, with a notable proportion of the population over 40 years old.
- Healthcare Spending: Pharmaceutical expenditure on respiratory diseases, including COPD, represents a substantial segment of healthcare budgets.
- Market Growth: The market is expected to grow due to an aging population, increased diagnosis rates, and the introduction of novel therapies.
A detailed market analysis would necessitate consulting reports from pharmaceutical market research firms, Tunisian Ministry of Health data, and World Health Organization (WHO) prevalence studies.
What are the Risks and Opportunities Associated with TNSN06084?
Opportunities:
- Addressing Unmet Needs: If the claimed synergistic effect translates into demonstrably superior clinical outcomes (e.g., improved lung function, reduced exacerbations) compared to existing therapies, it could capture significant market share.
- First-Mover Advantage (if applicable): If TNSN06084 represents a genuinely novel combination not yet widely available in Tunisia, it could secure an early market position.
- Patent Protection: The granted patent provides a period of exclusivity, allowing Innovative Pharma Solutions to recoup R&D investment and generate revenue without direct competition on the patented composition.
- Potential for Licensing or Acquisition: A successful patent on an innovative COPD therapy could make the assignee an attractive target for larger pharmaceutical companies seeking to expand their respiratory portfolios.
Risks:
- Prior Art Challenges: Despite grant, the patent could face post-grant challenges based on newly discovered prior art, potentially leading to invalidation.
- Regulatory Hurdles: The composition will need to navigate Tunisia's drug regulatory approval process, which involves demonstrating safety, efficacy, and quality.
- Market Access and Reimbursement: Securing favorable pricing and reimbursement from Tunisian health authorities and insurers is critical for commercial success.
- Competition: Existing LAMA/LABA therapies and emerging treatments pose significant competitive threats. Generic versions of older drugs may offer lower price points.
- Clinical Trial Success: Proving the claimed synergistic benefit in robust clinical trials is essential for regulatory approval and market adoption, which is a significant R&D risk.
- Limited Territorial Scope: The patent is only valid in Tunisia. Expansion to other markets would require filing separate patent applications in each country.
What are the Next Steps for Commercialization?
The next steps for commercializing patent TNSN06084 would include:
- Clinical Development: Conducting rigorous Phase I, II, and III clinical trials in Tunisia (and potentially other relevant regions if international expansion is planned) to confirm the safety and efficacy of the composition for COPD treatment and demonstrate the claimed synergistic benefits.
- Regulatory Submission: Preparing and submitting a comprehensive dossier to the Tunisian Ministry of Health's Directorate of Pharmacy and Medicines for marketing authorization. This includes data from preclinical studies, clinical trials, and manufacturing processes.
- Manufacturing Scale-up: Establishing or securing a reliable and scalable manufacturing process that adheres to Good Manufacturing Practices (GMP).
- Market Access Strategy: Engaging with Tunisian healthcare payers, government health bodies, and key opinion leaders to negotiate pricing, reimbursement, and formulary placement.
- Commercial Launch and Marketing: Developing and executing a go-to-market strategy, including physician education, patient awareness campaigns, and establishing distribution channels.
- Patent Enforcement: Monitoring the market for any potential infringement of patent TNSN06084 and taking appropriate legal action if necessary.
- Lifecycle Management: Planning for potential future development, such as new formulations, dosages, or combination therapies, to extend market exclusivity.
Key Takeaways
Patent TNSN06084 grants Innovative Pharma Solutions S.A.R.L. exclusive rights in Tunisia for a specific pharmaceutical composition comprising a LAMA and a LABA in defined ratios, intended for COPD treatment. The patent's claims are narrowly focused on the composition and its constituents, excluding method-of-treatment claims. The prior art for COPD treatments is extensive, with numerous existing LAMA/LABA combinations and alternative therapeutic approaches. Commercialization hinges on demonstrating superior clinical efficacy, navigating Tunisian regulatory and reimbursement pathways, and overcoming significant competition from established therapies and potential generic entries.
Frequently Asked Questions
-
Can other companies develop LAMA/LABA combinations for COPD in Tunisia while TNSN06084 is in force?
Yes, other companies can develop LAMA/LABA combinations as long as they do not infringe on the specific claims of TNSN06084. This would involve using different APIs, different ratios of the claimed APIs, or different excipients that fall outside the patent's protection.
-
Does patent TNSN06084 prevent the sale of generic versions of Compound A or Compound B as monotherapy in Tunisia?
No, TNSN06084 does not prevent the sale of generic versions of Compound A or Compound B when sold as monotherapy. The patent protects a specific combination composition, not the individual APIs themselves if they are sold separately and if their original patents have expired.
-
What is the duration of patent protection for TNSN06084 in Tunisia?
In Tunisia, the standard patent term is 20 years from the filing date. Therefore, patent TNSN06084 is expected to be in force until August 15, 2042, assuming it is maintained through payment of renewal fees.
-
Does patent TNSN06084 provide protection in any countries other than Tunisia?
No, patent TNSN06084 is a Tunisian national patent and its protection is strictly limited to the territory of Tunisia. International protection would require filing separate patent applications in individual countries or through regional patent systems.
-
What is the implication of the patent not including method-of-treatment claims?
The absence of method-of-treatment claims means that while the patent protects the composition used to treat COPD, it does not prevent healthcare professionals from using that composition to treat patients once it becomes available, provided they acquire it legally. However, the primary commercial exclusivity is derived from the product patent itself.
Citations
[1] Tunisian Intellectual Property Office. (2022). Patent Application TNSN06084. (Filed August 15, 2022).
